Zentiva calls meeting on Sanofi bid

Czech drugmaker Zentiva has called a special shareholders meeting Sept. 3 to consider Sanofi-Aventis' buyout offer--and to consider competing bids. Last month, Zentiva management told shareholders to reject the $1.86 billion bid because it didn't adequately reflect the company's value. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.